NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 15.84 against a street estimate of 12.16 — a beat of 30.3%.
with an average price target of ₹1,972.28.
CONFIDENT IPCA delivered 21% consolidated revenue growth to ₹2,788 cr with EBITDA margin expansion to 22.8%, driven by strong API (+30%), exports (+34%), and domestic formulations (+13%). Guidance raised to 14–16% FY27 growth. Q1 FY27 Europe/UK generics driving growth via supply issue resolution. U.S. growth 15–17% expected long-term. Brazil momentum improving. Logistics/freight costs escalating (South America containers 3,000→9,000–10,000; U.S. 7,000–7,500→12,500–13,000). Analysts pressed on U.S. sustainability (management capped at 15–17%), margin headwinds from freight (management said sales growth offsets), and guidance (management raised both top-line and EBITDA). Management also fielded questions on institutional business normalization (single-digit), Lyka turnaround, and biotech timeline (FY29–30 first revenue). 2026-08-14…
Full summary in the app.
| Document | Date |
|---|---|
| Q1 FY27 earnings call IPCA LABORATORIES LIMITED – Q1 FY27 EARNINGS SUMMARY HEADLINE NUMBERS • Consolidated Revenue: INR 2,788 crores in Q1 FY27 vs INR 2,309 crores in Q1 | 2026-08-17 |
| Quarterly results · Q1 FY27 IPCA LABORATORIES LIMITED – Q1 FY27 FINANCIAL SUMMARY HEADLINE NUMBERS • Standalone Revenue from Operations: ₹2,119.24 crores (Q1 FY27) vs ₹1,746.90 | 2026-08-13 |
| Annual report FY2026 IPCA LABORATORIES LIMITED – ANNUAL REPORT 2025-26 SUMMARY HEADLINE NUMBERS • Total Income FY 2025-26: ₹7,431.39 crores (vs ₹6,749.21 crores in FY 20 | 2026-07-14 |
| Q4 FY26 earnings call IPCA LABORATORIES LIMITED – Q4 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Consolidated Revenue FY26: INR 9,646 crores (+8% YoY from INR 8,940 crores) | 2026-06-04 |
| Quarterly results · Q4 FY26 IPCA LABORATORIES LIMITED – FINANCIAL RESULTS SUMMARY For Financial Year Ended March 31, 2026 --- HEADLINE NUMBERS • Full Year Revenue from Operati | 2026-05-29 |
| Q3 FY26 earnings call IPCA LABORATORIES LIMITED – Q3 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q3 FY26 consolidated revenue: INR 2,245 crores (down 6.5% YoY from INR 2,393 | 2026-02-18 |
| Quarterly results · Q3 FY26 IPCA LABORATORIES LIMITED – Q3 FY26 FINANCIAL SUMMARY HEADLINE NUMBERS • Q3 FY26 Standalone Revenue: ₹1,845.18 crores (vs ₹1,662.68 crores in Q3 FY2 | 2026-02-13 |
| Q2 FY26 earnings call IPCA LABORATORIES LIMITED – Q2 FY26 SUMMARY HEADLINE NUMBERS • Domestic Formulation Growth: 8% in Q2 FY26; guidance maintained at 10-11% for full ye | 2025-11-17 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹6 / share ex-date Aug 7, 2026 | 2026-08-07 |
| Announcement | Date |
|---|---|
| Amalgamation/Merger transaction announced IPCA Laboratories Limited has informed the Exchange about Amalgamation/Merger | 2026-06-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for IPCA Laboratories Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.